Press Releases

Poseida Therapeutics Announces FDA Clearance of Investigational New Drug Application for P-MUC1C-ALLO1, a Fully Allogeneic CAR-T Targeting Multiple Solid Tumors

December 20, 2021

Poseida Therapeutics Provides Update on BCMA-Targeted CAR-T Clinical Trials at the 2021 American Society of Hematology (ASH) Annual Meeting

December 13, 2021

Poseida Therapeutics Provides Program Updates and Financial Results for the Third Quarter of 2021

November 9, 2021

Poseida Therapeutics to Present Preclinical Data Highlighting Fully Allogeneic CAR-T Product Candidates at the Society for Immunotherapy of Cancer 2021 Annual Meeting

November 9, 2021

Poseida Therapeutics to Present at Upcoming Virtual Investor Conferences

November 3, 2021

Poseida Therapeutics Announces Leadership Appointments

October 13, 2021

Poseida Therapeutics Announces Research Collaboration with Takeda for Novel Non-Viral In Vivo Gene Therapies

October 12, 2021

Poseida Therapeutics to Present at Society for Immunotherapy of Cancer 2021 Annual Meeting

October 1, 2021

Poseida Therapeutics to Present at Upcoming Virtual Investor Conferences

September 7, 2021

Poseida Therapeutics Presents Preliminary Results from Phase 1 Trial of P-PSMA-101 at the 6th Annual CAR-TCR Summit

August 31, 2021